Vaxcyte, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 26/100
What the filing says
Vaxcyte, Inc. (market cap ~$3.7B) conducted concurrent public offerings on October 6–9, 2026: (1) 7.4125M common shares + 400K pre-funded warrants at $64.00/share, generating ~$473M net; (2) $500M of 1.50% convertible notes due 2032 (conversion price ~$89.60), generating ~$486M net. Combined net proceeds ~$959M. Underwriters: Jefferies and Leerink Partners (co-leads). Proceeds to fund VAX-31 clinical programs, manufacturing scale-up, and commercial preparation.
Why this rating
Large absolute raise (~$959M = 26% of market cap) but typical for clinical-stage biotech pre-commercialization. Funds core pipeline; no M&A or transformational deal. Dilutive to shareholders; positive liquidity event.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.